AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

NASDAQ:AMRX • US03168L1052

13.81 USD
-0.68 (-4.69%)
At close: Feb 27, 2026
13.55 USD
-0.26 (-1.88%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, AMRX scores 6 out of 10 in our fundamental rating. AMRX was compared to 192 industry peers in the Pharmaceuticals industry. AMRX has only an average score on both its financial health and profitability. AMRX is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make AMRX suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year AMRX was profitable.
  • AMRX had a positive operating cash flow in the past year.
  • AMRX had negative earnings in 4 of the past 5 years.
  • Of the past 5 years AMRX 4 years had a positive operating cash flow.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • With a decent Return On Assets value of 0.16%, AMRX is doing good in the industry, outperforming 78.13% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 10.43%, AMRX belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is below the industry average of 12.96%.
  • The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(10.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROIC 10.43%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.20%, AMRX is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
  • AMRX's Operating Margin of 12.32% is amongst the best of the industry. AMRX outperforms 85.42% of its industry peers.
  • AMRX's Operating Margin has improved in the last couple of years.
  • AMRX's Gross Margin of 36.76% is fine compared to the rest of the industry. AMRX outperforms 60.94% of its industry peers.
  • AMRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
  • AMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • AMRX has an Altman-Z score of 1.99. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.99, AMRX is in the better half of the industry, outperforming 63.02% of the companies in the same industry.
  • AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 11.13, AMRX belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Altman-Z 1.99
ROIC/WACC1.02
WACC10.25%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMRX (2.13) is comparable to the rest of the industry.
  • AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
  • AMRX has a Quick ratio of 1.42. This is in the lower half of the industry: AMRX underperforms 64.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.42
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.00% over the past year.
  • Measured over the past years, AMRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.63% on average per year.
  • The Revenue has grown by 16.73% in the past year. This is quite good.
  • The Revenue has been growing by 11.43% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
  • AMRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.
EPS Next Y40.07%
EPS Next 2Y28.33%
EPS Next 3Y26.86%
EPS Next 5Y11.95%
Revenue Next Year8.67%
Revenue Next 2Y7.55%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 18.41, the valuation of AMRX can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 85.42% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.10. AMRX is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 14.46, AMRX is valued correctly.
  • Based on the Price/Forward Earnings ratio, AMRX is valued cheaper than 83.33% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, AMRX is valued a bit cheaper.
Industry RankSector Rank
PE 18.41
Fwd PE 14.46
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, AMRX is valued cheaper than 85.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.36
EV/EBITDA 11.61
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AMRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AMRX's earnings are expected to grow with 26.86% in the coming years.
PEG (NY)0.46
PEG (5Y)1.73
EPS Next 2Y28.33%
EPS Next 3Y26.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (2/27/2026, 8:00:00 PM)

After market: 13.55 -0.26 (-1.88%)

13.81

-0.68 (-4.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners45.17%
Inst Owner Change-0.49%
Ins Owners46.29%
Ins Owner Change-0.38%
Market Cap4.34B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (7.1%)
Short Float %8.12%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)0%
PT rev (3m)8.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-1.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE 18.41
Fwd PE 14.46
P/S 1.48
P/FCF 18.36
P/OCF 13.25
P/B N/A
P/tB N/A
EV/EBITDA 11.61
EPS(TTM)0.75
EY5.43%
EPS(NY)0.96
Fwd EY6.92%
FCF(TTM)0.75
FCFY5.45%
OCF(TTM)1.04
OCFY7.55%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.46
PEG (5Y)1.73
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROCE 13.2%
ROIC 10.43%
ROICexc 11.26%
ROICexgc 21.11%
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
FCFM 8.06%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Debt/EBITDA 4.36
Cap/Depr 37.95%
Cap/Sales 3.11%
Interest Coverage 1.67
Cash Conversion 54.45%
Profit Quality 4008.53%
Current Ratio 2.13
Quick Ratio 1.42
Altman-Z 1.99
F-Score7
WACC10.25%
ROIC/WACC1.02
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.07%
EPS Next 2Y28.33%
EPS Next 3Y26.86%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.67%
Revenue Next 2Y7.55%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.93%
EBIT Next 3Y11.51%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.


How financially healthy is AMNEAL PHARMACEUTICALS INC?

The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 5 / 10.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.07% in the next year.